尼达尼布对系统性硬化症相关间质性肺疾病(SSc-ILD)患者的基线综合生理指数(CPI)影响

A. Wells, K. Highland, S. Gläser, H. Nunes, J.W. Song, W. Wuyts, C. Stock, M. Alves, M. Padilla, on behalf of the SENSCIS trial investigators
{"title":"尼达尼布对系统性硬化症相关间质性肺疾病(SSc-ILD)患者的基线综合生理指数(CPI)影响","authors":"A. Wells, K. Highland, S. Gläser, H. Nunes, J.W. Song, W. Wuyts, C. Stock, M. Alves, M. Padilla, on behalf of the SENSCIS trial investigators","doi":"10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a2433","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":131426,"journal":{"name":"B22. EMERGING MANAGEMENT OF FIBROTIC ILDs","volume":"44 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2022-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Effect of Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) by Composite Physiologic Index (CPI) at Baseline\",\"authors\":\"A. Wells, K. Highland, S. Gläser, H. Nunes, J.W. Song, W. Wuyts, C. Stock, M. Alves, M. Padilla, on behalf of the SENSCIS trial investigators\",\"doi\":\"10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a2433\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":131426,\"journal\":{\"name\":\"B22. EMERGING MANAGEMENT OF FIBROTIC ILDs\",\"volume\":\"44 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"B22. EMERGING MANAGEMENT OF FIBROTIC ILDs\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a2433\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"B22. EMERGING MANAGEMENT OF FIBROTIC ILDs","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a2433","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Effect of Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) by Composite Physiologic Index (CPI) at Baseline
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Clinical Evaluation of Cudetaxestat for Safety,Tolerability, Pharmacokinetics, Pharmacodynamics, and Potential Drug-Drug Interactions Elastin Specific Molecular Imaging for Pulmonary Fibrosis Sildenafil Added to Pirfenidone in Patients with Advanced Idiopathic Pulmonary Fibrosis (IPF) and Risk of Pulmonary Hypertension (PH): Results of a Responder Analysis Polarization Sensitive Endobronchial Optical Coherence Tomography for In Vivo Microscopic Assessment of Pulmonary Fibrosis Real-World Evaluation of the Impact of the Anti-fibrotics in Patients with Idiopathic Pulmonary Fibrosis and Other Fibrotic Lung Diseases
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1